Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma

Pei-Yuan Li, Ju-Sheng Lin, Zuo-Hua Feng, Yu-Fei He, He-Jun Zhou, Xin Ma, Xiao-Kun Cai, De-An Tian

AIM: To study the antitumor effect of combined gene therapy of endostatin and interleukin 12 (IL-12) with polyvinylpyrrolidone (PVP) on mouse transplanted hepatoma.

METHODS: Mouse endostatin eukaryotic plasmid (pSecES) with a mouse Igκ signal sequence inside and mouse IL-12 eukaryotic plasmid (pmIL-12) were transfected into BHK-21 cells respectively. Endostatin and IL-12 were assayed by ELISA from the supernatant and used to culture endothelial cells and spleen lymphocytes individually. Proliferation of the latter was evaluated by MTT. H22 cells were inoculated into the leg muscle of mouse, which was injected intratumorally with pSecES/PVP, pmIL-12/PVP or pSecES+pmIL-12/PVP repeatedly. Tumor weight, serum endostatin and serum IL-12 were assayed. Tumor infiltrating lymphocytes, tumor microvessel density and apoptosis of tumor cells were also displayed by HE staining, CD31 staining and TUNEL.

RESULTS: Endostatin and IL-12 were secreted after transfection, which could inhibit the proliferation of endothelial cells or promote the proliferation of spleen lymphocytes. Tumor growth was highly inhibited by 91.8% after injection of pSecES+pmIL-12/PVP accompanied by higher serum endostatin and IL-12, more infiltrating lymphocytes, fewer tumor vessels and more apoptosis cells compared with injection of pSecES/PVP, pmIL-12/PVP or vector/PVP.

CONCLUSION: Mouse endostatin gene and IL-12 gene can be expressed after intratumoral injection with PVP. Angiogenesis of hepatoma can be inhibited synergistically, lymphocytes can be activated to infiltrate, and tumor cells are induced to apoptosis. Hepatoma can be highly inhibited or eradicated.

INTRODUCTION
Liver cancer is one of the most common neoplasms worldwide. In some parts of Asia and Africa the prevalence is more than 100/100 000 population[11]. Treatments often come to failure because of its high resistance to chemotherapy or radiotherapy and the severe side-effects induced[11]. At present the only curative options are partial hepaeectomy or total hepaeectomy with liver transplantation. But the chance for surgery is very limited. The effects of some other treatments such as intratumoral injection of ethanol or acetic acid, transarterier catheter embolization, and thermal destruction or microwave coagulation were also very poor due to the high incidence of tumor recurrence and hepatic failure[1-3]. Now combined treatments including biotherapy have been regarded as the most promising methods to cure liver cancer[4,5].

More and more learners have begun to realize that the occurrence of tumors is a complex course induced by multiple genes and multiple steps. Interference of single factor on tumor often can not get satisfactory results. Although primary tumors were regressed to dormant microscopic lesions after endostatin therapy, tumor cells were not eradicated at all[12,13]. Conventional chemotherapy or radiotherapy can do little on residual tumor cells, accurate recognition and clearance of which depends on the immune system of host[11]. IL-12 is among the most potent cytokines in stimulating antitumor immunity[14-16], which also showed significant inhibitory activity on angiogenesis[15]. So antiangiogenesis therapy by endosatin in combination with antitumor immunotherapy by IL-12 has become an attractive approach. On one hand synergistically antiangiogenic effect may be achieved to induce tumor dormancy. On the other hand, residual tumor cells may be also eradicated by antitumor immunotherapy induced by IL-12. Due to the problems such as bioactive protein production in large quantities, high costs and daily administration of endostatin[10,15], and the severe side-effects of system administration of IL-12[17,18], local gene therapy has proved to be very effective and nontoxic at the same time[19-24]. This study combined intratumoral gene therapy of endostatin and IL-12 was observed in treatment of mouse hepatoma.

MATERIALS AND METHODS
Plasmid and host
Mouse endostatin eukaryote expression plasmid pSecES was constructed in our laboratory (data not shown). The expression of endostatin was under the control of cytomegalovirus (CMV) promoter. A mouse Igκ signal peptide sequence was located upstream of endostatin sequence to lead endostatin to secrete out. Mouse IL-12 eukaryote expression plasmid (pmIL-12) was

Abstract

AIM: To study the antitumor effect of combined gene therapy of endostatin and interleukin 12 (IL-12) with polyvinylpyrrolidone (PVP) on mouse transplanted hepatoma.
a gift from Professor David M. Mahvi in Wisconsin University, USA. Both M, 35 000 light chain gene and M, 40 000 heavy chain gene linked by an internal ribosome entrance site were put downstream of CMV promoter[23]. Empty plasmid pcDNA3.1, pcDNA3.1-lacZ and E.coli DH5α were from the collection of our laboratory. DH5α bacteria containing the plasmids were grown in LB medium to mid-log phase. The plasmids were then purified with Qiagen columns (Qiagen). An analytical gel of each plasmid (cut and uncut) was done to ensure that there was no contamination with other nucleic acids. The A260/A280 ratios ranged from 1.8 to 2.0. Also each plasmid was confirmed to be free of endotoxin. For gene therapy, concentrated plasmid stock solution was made by lyophilizing and rehydrating with water. Then it was formulated into a solution containing 1 g/L plasmid, 50 g/L polyvinylpyrrolidone (PVP, K30, from Sigma), 100 µg/L penicillin and 100 mg/L streptomycin. Cells were cultured at 37 ℃.

Cell culture and animals

BHK-21, human umbilical vein endothelial cell line (HUVEC) ECV304 and mouse hepatoma cell line H22 were purchased from China Center for Type Culture Collection. All the cell lines were maintained in RPMI 1640 medium (GibcoBRL) supplemented with 100 m/L fetal bovine serum (FBS), 10 µ/L penicillin and 100 mg/L streptomycin. Cells were cultured at 37 ℃ with 50 mL/L CO2. Six to 8-wk-old male BALB/c mice of specific-pathogeny-free (SPF) grade (purchased from Hubei Experimental Animals Center, China) were maintained in a standard SPF animal’s room. All animal studies were performed in accordance with acceptable animal use guidelines.

Secretion and activity of endostatin plasmid and IL-12 plasmid

In 6-well plate, 5×105 BHK-21 cells per well were transfected with 1 µg pcSecES or 1 µg pmiIL-12, 3 µL Lipofectamine 2000 (InvivoGen) in accordance with directions of the manufacturer. Forty-eight hours after transfection, 0.1 mL ECV304 cells (2×105/L) cultured in RPMI 1640 additionally supplemented with 2 µg/L recombinant human basic fibro growth factor (rhbFGF) (PeproTech, UK) was inoculated to a 96-well plate. 0.1 mL supernatant of BHK-21 cells transfected with pcSecES was added to ECV304 cells per well. Seventy-two hours later, 20 µL 5 g/L MTT was added per well. After 4 h, the supernatant was discarded and 150 µL DMSO was added. Absorbency at 570 nm was assayed. Forty-eight hours after transfection, mouse spleen cells were also produced by routine protocols and cultured in RPMI 1640 medium supplemented with 100 m/L FBS for 2 h. Then the suspending lymphocytes were added to 1×107/L and seeded to a 24-well plate (0.5 mL per well). 0.5 mL supernatant of BHK-21 cells transfected with pmiIL-12 was added per well. Forty-eight hours later, the proliferation was evaluated by MTT assay as above. The supernatant of BHK-21 transfected with pcDNA3.1-lacZ was used as control. Also transfection rate was evaluated by X-gal staining of BHK-21 transfected with pcDNA3.1-lacZ 48 h later. All the three kinds of supernatant was stored at –20 ℃ for further assay.

Combined gene therapy of endostatin and IL-12 for H22 hepatoma in vivo

In 0.1 mL PBS, 1×107 H22 cells were inoculated i.m. into the hind limb of BALB/c mice. Then the mice were randomly divided into five groups (6 per group): PVP/NaCl (untreated), pcDNA3.1 (empty vector), pSecES, pmiIL-12, pcSecES-pmiIL-12. Another 6 mice were not inoculated for further assay of basic serum endostatin. From the next day after inoculation, 100 µg pcSecES/PVP and/or pmiIL-12/PVP, 100 µg pcDNA3.1/PVP or 100 µL PVP/NaCl solution was injected into the inoculation site respectively with a 26 G needle every three days. After inoculation for 21 days, tumors were removed and weighed. Before tumor dissection, mouse blood was collected and stored at 4 ℃. Then the serum was stored at –20 ℃ for further assay after centrifugation. The data were analyzed statistically by SPSS 10.0 procedure.

Assay of mouse endostatin and IL-12 (p70) in supernatant or serum

The frozen supernatant of BHK-21 transfected with pSecES, pmiIL-12 or pcDNA3.1-lacZ and the frozen serum were thawed to room temperature. Then mouse endostatin and IL-12 (p70) were assayed according to the directions of CyTImmune mouse endostatin kit (CyTImmune, USA) and mouse IL-12 (p70) ELISA kit (Shengzhen Jingmei Biotech, China).

Detection of MVD, TILs and apoptosis of H22 hepatoma

Paraffin sections (5 µm) of tumor tissues were stained with rat anti-mouse CD31 antibody (eBioscience). The primary antibody was detected by biotinylated secondary rabbit anti-rat IgG and SABC immunohistochemistry kit (Wuhan Boster Biotech, China) according to directions of its manufacturer. Paraffin sections were also stained with HE to reveal tumor infiltrating lymphocytes (TILs). Apoptosis of tumors was displayed by TdT-mediated dUTP nick end labeling (TUNEL) staining with an in situ cell death detection kit (Boehringer Mannheim, Germany) in accordance with the guideline of its manufacturer.

Tumor microvessel density (MVD) was counted as previously described[26,27]. The CD31 staining sections were scanned in 40x microscope and “hot spots” (area with greatest vascula) were found, from which 3 random fields of 200x microscope were selected. The average vascular number of the three fields was looked as MVD. For HE and TUNEL staining sections, 5 random nonnecrotic tissue fields in 400x microscope was selected. The average number of TILs or apoptotic cells was counted. The data were analyzed statistically by SPSS 10.0 procedure.

RESULTS

Secretion and activity of endostatin plasmid and IL-12 plasmid

β-galactosidase expression was assayed by X-gal staining 48 h post-transfection. The transfection efficiency was about 30%. No endostatin or IL-12 was detected in the supernant of BHK-21 transfected with pcDNA3.1-lacZ. Endostatin secreted by BHK-21 transfected with pSecES was 65.5±10.9 ng/106 cells. When this supernatant was added to ECV304 stimulated by rhbFGF, the proliferation of the latter was inhibited by 29.2% 72 h later (inhibitory efficiency= A of endostatin group/A of control group, P<0.01). Also 221.8±44.4 ng/106 cells IL-12 (p70) was detected in the supernant of BHK-21 transfected with pmiIL-12. It could promote mouse spleen lymphocytes to proliferate by 15.2% (proliferation efficiency= A of IL-12 group/A of control group, P<0.05). The results are displayed in Figure 1.

Antitumor effect of combined gene therapy of endostatin and IL-12 for H22 hepatoma in vivo

On the next day after inoculation, the mice received gene therapy. No skin lesions were found in the injection sites. On d 21 after inoculation, tumors were dissected and weighed. Big tumors could be found in all mice of PVP/NS group and pcDNA3.1 group. In pSecES group, all mice formed tumors, some of which were much smaller. Four mice formed tumors in pmiIL-12 group and only two mice formed small tumors in pcSecES-pmiIL-12 group. The average tumor weight of pSecES group was much lower than that of PVP/NS group or pcDNA3.1 group (P<0.01) (Figure 2). The inhibitory rate was 56.4% (inhibitory efficiency=1- tumor weight of pSecES group/tumor weight of control group) (P<0.01) (Figure 2). The inhibitory rate was 56.4% (inhibitory efficiency=1- tumor weight of pSecES group/tumor weight of control group) (P<0.01).
weight of pcDNA3.1 group). For pmIL-12 group, the inhibitory rate was 85.7%. When pSecES gene therapy and pmIL-12 gene therapy were used in combination, tumor growth was inhibited by 91.8% ($P<0.01$).

**Figure 1** Proliferation of ECV304 inhibited by the supernatant of BHK-21 transfected with pSecES and proliferation of spleen lymphocytes stimulated by the supernatant of BHK-21 transfected with pmIL-12. Each bar represents $A$ value of ECV304 or spleen lymphocytes, and mean±SD for 5 wells. $a$ $P<0.05$ vs control, $b$ $P<0.01$ vs control.

**Figure 2** Hepatoma formation and growth inhibited by gene therapy of endostatin and IL-12. Each bar represents tumor weight of mice treated with PVP/NaCl, pcDNA3.1/PVP, pSecES/PVP, pmIL-12/PVP or pSecES+pmIL-12/PVP, and mean±SD for six mice. $P<0.01$ by ANOVA analysis.

**Serum endostatin and IL-12 levels after gene therapy**

When gene therapy was finished, the serum endostatin and IL-12 levels were evaluated by ELISA. The serum endostatin level in pSecES group was $117.1\pm12.8$ µg/L, which was much higher than that in pcDNA3.1 group ($87.7\pm6.1$ µg/L) or the basic level

**Figure 3** Increase of mice serum endostatin levels or IL-12 levels after gene therapy. A: Serum endostatin levels of mice treated with pcDNA3.1/PVP, pSecES/PVP, pSecES+pmIL-12/PVP or not inoculated with H22 cells (basic levels). Each bar represents mean±SD for six mice. $a$ $P<0.05$ vs pcDNA3.1 group. B: Serum IL-12 levels of mice treated with pcDNA3.1/PVP, pmIL-12/PVP, pSecES+pmIL-12/PVP. Each bar represents mean±SD for six mice. $a$ $P<0.05$ vs pcDNA3.1 group.

**Figure 4** Hepatoma angiogenesis inhibited by gene therapy of endostatin and IL-12. MVD (CD31staining, 200×) of hepatoma treated with pSecES/PVP ($7.3\pm1.2$) (B), pmIL-12/PVP ($10.0\pm1.7$) (C) or pSecES+pmIL-12/PVP ($3.7\pm1.2$) (D) was less than that treated with pcDNA3.1/PVP ($22.7\pm3.1$, $P<0.05$) (A).
MVD, TILs and apoptosis of H22 hepatoma after gene therapy

MVD were counted after CD31 staining in tumor sections. Compared with pcDNA3.1 group, MVD of hepatoma treated with pSecES/PVP or pmIL-12/PVP were much less. And in pSecES+pmIL-12 group, MVD were less than any single gene therapy group (P <0.05) (Figure 4).

Tumor sections were stained by HE, then TILs were evaluated. After pmIL-12/PVP or pSecES+pmIL-12 gene therapy, TILs in hepatoma were more than that treated with pcDNA3.1/PVP (45.2±11.8, P <0.01) (A).

Also, tumor apoptosis was displayed by TUNEL staining. Figure 6 shows that there were only a few apoptotic tumor cells dispersed in 400× random scopes in pcDNA3.1 group. But in pSecES group or pmIL-12 group, apoptotic tumor cells increased. In pSecES+pmIL-12 group, apoptotic tumor cells were much more than any group (P<0.05).

DISCUSSION

Despite the progress in early diagnosis of liver cancer, its prognosis remains poor. In average, the mean life span was less than a year after diagnosis[1]. How to prevent or cure the recurrence of remained tumor cells after partial hepatectomy and how to inhibit tumor infiltrating in liver cancer patients in advanced stage are urgent challenges for liver cancer therapy.

Now antiangiogenic therapy and immunotherapy have been paid more and more attention and many promising conclusions have been drawn[28-31]. But in clinical trails, few satisfactory results were obtained by single biotherapy[17,18,32]. Whether synergistic effects of antiangiogenesis therapy in combination with immunotherapy could be achieved is worthy to be researched.

Studies showed that angiogenesis played a very important role in the course of growth and metastasis of solid tumors including liver cancer. When the tumor size was beyond 2-3 mm³, oxygen and nutrition were not enough by simple diffusion. Then new vessels must be formed for further growth[33]. However, angiogenesis was dependent on the cooperation of pro-angiogenesis factors and anti-angiogenesis factors[34]. Among many inhibitors, endostatin, the C terminal of collagen X VIII, which is a Mr 20000 protein with 184 amino acids in primary structure, has the strongest antiangiogenesis and antitumor effect. It was identified from the medium of a murine hemangiendothelioma (EOMA) cell line in 1997[7]. Researchers indicated that both natural and recombinant endostatin could markedly inhibit endothelial cell proliferation in vitro and angiogenesis in chick chorioallantoic membrane, but had no effect on non-endothelial cells. When endostatin was administrated subcutaneously, primary tumors were regressed to dormant microscopic lesions and metastasis was inhibited. Repeated cycles of endostatin therapy showed prolonged tumor dormancy without further therapy[7,10]. In our previous study, subcutaneous
induced more or less. IL-12 is among the most potent proliferation of immunocytes and antitumor immunity were immune response either TNF-α linked heterodimeric cytokine. IL-12 acts by inducting a TH1 type of response, activating natural killer cells and cytotoxic T lymphocytes, enhancing expression of adhesion molecules on endothelial cells, thus facilitating the traffic of lymphocytes to the tumor, and inducting a potent antiangiogenesis effect. In previous researches, the antitumor effect of IL-12 was established in various in vivo systems. However, the latter was reported to cause fatal toxicity in a clinical trial, which led investigators to local administration of this cytokine by gene therapy or gene gun, that proved to be very effective and nontoxic at the same time. In our study, active IL-12 (p70) was expressed in vitro and in vivo. Tumors did not formed in 30% mice that received IL-12 gene therapy. The formed tumors were also highly inhibited with more TILs, less MVD and more apoptotic tumor cells. Moreover, the inhibitory effect of IL-12 gene therapy on H22 hepatoma was much better than that of endostatin plasmid (P<0.05).

When combined gene therapy of endostatin and IL-12 was used, its antitumor effect was much better than others. Tumor formation was not observed in 66.7% mice. The average tumor weight inhibitory rate was 91.8%. But in mice that received endostatin gene therapy, no tumor regressed. The average tumor weight inhibitory rate was 56.4%. No tumor was formed in 33.3% mice after they received IL-12 gene therapy. The average tumor weight inhibitory rate was 85.7%. It was suggested that synergistic antitumor effect was achieved after combined gene therapy of endostatin and IL-12. The proposed mechanism of the combined gene therapy maybe a synergistic cooperation of an antiangiogenesis effect induced by endostatin and IL-12 in combination with an immune rejection induced by IL-12. On one hand, endostatin and IL-12, which were expressed locally in combination with increased serum levels after gene delivery mediated by plasmid with PVP, could inhibit angiogenesis of hepatoma synergistically. This was convinced by that MVD in pSecES±pIL-12 group was much less than any single gene therapy group. But now the antiangiogenesis mechanism of endostatin and IL-12 was still not very clear. Through this way, H22 hepatoma cells came to apoptosis or necrosis due to lack of blood supply. On the other hand, more TILs (including activated CTL, NK, TH1 etc.) were observed in tumors that received IL-12 gene therapy or combined gene therapy, which maybe an indication of activated immune response on H22 hepatoma cells. Antitumor immune rejection induced by IL-12 through immunocytes or cytokines also promoted apoptosis of tumor cells. So there were much more apoptotic tumor cells in combined gene therapy group than any single one. Due to these factors, formation and growth of transplanted H22 hepatoma was prevented synergistically.

Combined gene therapies for liver cancer were also reported previously. Learners have focused on combined genes of two or three immunocytokines, or on suicide gene therapy in combination with genetic immunotherapy. Biotherapy in combination with chemotherapy for lymphoma was also studied. Before our reports, combined treatment with type 5 adenovirus vectors expressing murine angiostatin and IL-12 showed an antitumor effect on a murine breast cancer. Our report is the first to demonstrate the potent antitumor effect of combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone on hepatoma.

In conclusion, active target protein can be expressed by repeated local injections of plasmid with PVP. Through this way, a short-term course of combined gene therapy of endostatin and IL-12 can effectively prevent the formation and development of transplanted H22 hepatoma in mice. Antiangiogenic therapy in combination with immunotherapy may be used to regress or to eradicate other solid tumors.

**REFERENCES**

1. Badvie S. Hepatocellular carcinoma. Postgrad Med j 2000; 76: 4-11
2. Zibari GB, Riche A, Zizzli HC, McMllian RW, Aultman DF, Boykin KN, Gonzalez E, N andy I, Dies DF, Gholson CF, Holcombe RF, McDonald JC. Surgical and nonsurgical management of primary and metastatic liver tumors. Am Surg 1998; 64: 211-220
3. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32(1 Suppl): 225-237
4. Kamohara Y, Kanematsu T. Treatment of liver cancer: current status and future perspectives. Ganto Kagaku Ryuoho 2000; 27: 987-992
5. Sorokin P. New agents and future directions in biotherapy. Clin Oncol Nurs 2002; 6: 19-24
zyme cDNA. Yang NS. Synergistic inhibition of tumor growth in a murine model of colon cancer therapy. Current pathologic methods for measuring angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 359: 58-67.

Folkman J, Watson K, Ingbir D, Hanahan D. Induction of angiostatin from a question of choice. Lollini PL, Forni G. Cytokine, tumor-cell death and immunogenicity: a question of paradox. Cancer Gene Ther 2001; 8: 478-481.

Cavallaro U, Christofori G. Mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000; 50: 63-70.

Li PY, Feng ZH, Zhang GM, Zhang H, Xue SL, Huang B, Lin JS. Inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of human liver carcinoma. J Huazhong Univ Sci Tech [Med Sci] 2003; 23: 223-226.

Chen CT, Lin J, Li Q, Phipps SS, Jakubczak JL, Stewart DA, Skripchenko Y, Forry-Schaudies S, Wood J, Schnell C, Hallenbeck PL. Antiangiogenic gene therapy for cancer via systemic administration of adenoaviral vectors expressing secretable endostatin. Hum Gene Ther 2000; 11: 1983-1996.

Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukui N, Shapiro R, Quei L, Lowik C, Timpano BR. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414-4423.

Prince HM. Gene transfer: A review of methods and applications. Pathology 1998; 30: 335-347.

Mumper RJ, Duguid GJ, Anker W, Kranz PK, Macta H, Rolland AP. Polyvinyl derivatives as novel interactive polymers for controlled gene delivery to the muscle. Pharmazie 2001; 56: 703-709.

Quezada A, Horner MJ, Loera D, French M, Pericile F, Johnson R, Perrard J, Jenkins M, Coleman M. Safety toxicity study of plasmid-based IL-12 therapy in Cynomolgus monkeys. J Pharm Pharmacol 2002; 54: 241-248.

Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC, Keating M, Albitar M. Clinical significance of plasma endostatin in acute myeloid leukaemia/myelodysplastic syndrome. Cancer 2002; 94: 14-17.

Suzuki M, Izasa T, Ko E, Baba M, Saltb Y, Shibuya K, Sekine Y, Yoshida S, Hirokima F, Fujisawa T. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35: 29-34.

Sakai Y, Kaneko S, Nakamoto Y, Kagaya T, Mukaida N, Kobayashi K. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase ganciclovir system by codelivering monocyte chemotactattract protein-1 in hepatic cell carcinoma. Cancer Gene Ther 2001; 8: 605-704.

Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrari PF, Martinelli G, Pruner G. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96: 282-287.

Gyorffy S, Palmer K, Podor T, Hilt M, Gauldie J. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy. J Immunol 2001; 166: 6212-6217.